Cumberland Pharmaceuticals (NASDAQ:CPIX) Shares Cross Above 200-Day Moving Average - What's Next?

Shares of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX - Get Free Report) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $4.21 and traded as high as $4.90. Cumberland Pharmaceuticals shares last traded at $3.93, with a volume of 265,680 shares.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded Cumberland Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, May 8th.

Cumberland Pharmaceuticals Price Performance

The company has a 50-day moving average of $4.97 and a 200-day moving average of $4.21. The stock has a market capitalization of $38.90 million, a price-to-earnings ratio of -10.40 and a beta of -0.29. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.09 and a current ratio of 1.25.

Cumberland Pharmaceuticals (NASDAQ:CPIX - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $0.15 earnings per share (EPS) for the quarter. Cumberland Pharmaceuticals had a positive return on equity of 6.92% and a negative net margin of 7.98%.

Institutional Investors Weigh In On Cumberland Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Berkshire Asset Management LLC PA acquired a new stake in Cumberland Pharmaceuticals during the first quarter worth approximately $692,000. Adage Capital Partners GP L.L.C. purchased a new position in Cumberland Pharmaceuticals during the first quarter worth about $634,000. Informed Momentum Co LLC acquired a new stake in Cumberland Pharmaceuticals in the 1st quarter worth about $304,000. Walleye Capital LLC purchased a new stake in Cumberland Pharmaceuticals in the 1st quarter valued at about $298,000. Finally, Two Sigma Investments LP increased its stake in shares of Cumberland Pharmaceuticals by 94.3% during the 4th quarter. Two Sigma Investments LP now owns 37,649 shares of the specialty pharmaceutical company's stock valued at $89,000 after acquiring an additional 18,271 shares during the last quarter. 15.51% of the stock is currently owned by hedge funds and other institutional investors.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.